Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Nat Commun ; 13(1): 5536, 2022 10 06.
Artículo en Inglés | MEDLINE | ID: mdl-36202800

RESUMEN

The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6-11.5) and 56.8% (95% CI, 56.3-57.3) in the period 8-59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9-80.7) and 86.0% (95% CI, 84.5-87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Adulto , Vacuna BNT162 , Brasil/epidemiología , COVID-19/epidemiología , COVID-19/prevención & control , Estudios de Casos y Controles , Humanos , Vacunas de Productos Inactivados
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA